Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1718277

registered interest
date	15/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that patients taking pancreatic enzymes continue to receive them.
tabling member constituency	Walthamstow
tabling member printed	Stella Creasy
uin	26452
answer	answer is ministerial correction date of answer 20/05/2024 answer text <p>We are aware of supply issues with three pancreatic enzyme replacement therapies: Creon 10000 gastro-resistant capsules; Creon 25000 gastro-resistant capsules; and Nutrizym 22 gastro-resistant capsules. We understand that these are due to limited availability of active pharmaceutical ingredients, and manufacturing constraints in producing the volumes required to meet demand. The Department has issued guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products, to ask that they expedite deliveries and increase production forecasts, and to confirm that they are taking action to address the root causes of the issues, to ensure continuity of supply. We are also working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 20/05/2024 16:55:17 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4088 label Biography information for Stella Creasy

1716806

registered interest
date	09/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of the availability of enzyme replacement therapy.
tabling member constituency	Jarrow
tabling member printed	Kate Osborne
uin	25591
answer	answer is ministerial correction date of answer 15/05/2024 answer text <p>We are aware of the supply issues with the three enzyme replacement therapies, Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The Department will be issuing updated guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to help drive the resolution of these issues as quickly as possible, for example by expediting orders and increasing forecasts. We are also working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 25370 25371 question first answered 15/05/2024 08:18:01 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4783 label Biography information for Kate Osborne

1716571

registered interest
date	08/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that people who require enzyme replacement therapy receive that medication in a timely manner.
tabling member constituency	Jarrow
tabling member printed	Kate Osborne
uin	25370
answer	answer is ministerial correction date of answer 15/05/2024 answer text <p>We are aware of the supply issues with the three enzyme replacement therapies, Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The Department will be issuing updated guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to help drive the resolution of these issues as quickly as possible, for example by expediting orders and increasing forecasts. We are also working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 25371 25591 question first answered 15/05/2024 08:18:00 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4783 label Biography information for Kate Osborne

1545285

registered interest
date	24/11/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether there has been an increase in the number of people with pancreatic cancer being prescribed Pancreatic Enzyme Replacement Therapy in the last year.
tabling member constituency	Warrington North
tabling member printed	Charlotte Nichols
uin	95955
answer	answer is ministerial correction date of answer 12/12/2022 answer text <p>This information requested is not collected.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 12/12/2022 17:41:22 answering member 4527 label Biography information for Helen Whately
tabling member	4799 label Biography information for Charlotte Nichols

1351230

registered interest
date	18/08/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that pancreatic cancer patients receive treatment within 20 days of diagnosis.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	40850
answer	answer is ministerial correction date of answer 06/09/2021 answer text <p>The Government is committed to the Long Term Plan ambition of diagnosing three quarters of cancers at Stage one or two by 2028. NHS England and NHS Improvement are taking a multi-pronged approach which includes accelerating access to diagnosis and treatment, through their rollout of Rapid Diagnostic Centres and the new Faster Diagnosis Standard and the investment in new equipment such as the £325 million capital funding for National Health Service (NHS) diagnostics, which is enough to replace over two thirds of imaging equipment over 10 years old. The investment in this Long Term Plan commitment will help improve early diagnosis and detection of pancreatic cancer.</p><p>NHS England and NHS Improvement have recently announced that they will commission an audit in pancreatic cancer to help to reduce variations in treatment and improve patient outcomes. Scoping for this audit has begun, and the first data is expected in 2023.</p><p>The National Institute of Health and Care Excellence (NICE) clinical guideline on the diagnosis and management of pancreatic cancer describes best practice in the care and treatment of patients with pancreatic cancer, including supporting their nutritional needs. Whilst NHS organisations and clinicians should take guidelines and quality standards into account, it is the responsibility of clinicians to make decisions appropriate to the circumstances of each patient.</p><p>The “Help Us to Help You” campaign encourages people with symptoms to come forward. Cancer referrals in April and May 2021 were at an all-time high. An additional £1bn funding has been made available to the NHS in 2021/22 to support the start of this recovery of elective activity, including the recovery of cancer services.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 40849 40851 question first answered 06/09/2021 16:53:42 answering member 4380 label Biography information for Jo Churchill
tabling member	3973 label Biography information for Grahame Morris

1344064

registered interest
date	06/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what proportion of pancreatic cancer patients were prescribed pancreatic enzyme replacement therapy in England in (a) 2015, (b) 2016, (c) 2017, (d) 2018 and (e) 2019.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	28227
answer	answer is ministerial correction date of answer 14/07/2021 answer text <p>The information requested is not held centrally. While the NHS Business Services Authority holds prescription data relating to drugs dispensed within a community setting, no data is collected on the clinical condition of the patient.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 14/07/2021 09:42:54 answering member 4380 label Biography information for Jo Churchill
tabling member	4433 label Biography information for Thangam Debbonaire

1344065

registered interest
date	06/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the prescription rates of pancreatic enzyme replacement therapy for inoperable pancreatic cancer patients in England who are not treated in specialist centres.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	28228
answer	answer is ministerial correction date of answer 08/07/2021 answer text <p>I refer the hon. Member to the answer I gave to the hon. Member for Slough (Mr Tanmanjeet Singh Dhesi MP) on 10 June 2021 to Question <a href="https://questions-statements.parliament.uk/written-questions/detail/2021-06-07/11722" target="_blank">11722</a>.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 28229 question first answered 08/07/2021 16:50:42 answering member 4380 label Biography information for Jo Churchill
tabling member	4433 label Biography information for Thangam Debbonaire

1344066

registered interest
date	06/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure pancreatic cancer patients are considered for pancreatic enzyme replacement therapy at the point of diagnosis in England.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	28229
answer	answer is ministerial correction date of answer 08/07/2021 answer text <p>I refer the hon. Member to the answer I gave to the hon. Member for Slough (Mr Tanmanjeet Singh Dhesi MP) on 10 June 2021 to Question <a href="https://questions-statements.parliament.uk/written-questions/detail/2021-06-07/11722" target="_blank">11722</a>.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 28228 question first answered 08/07/2021 16:50:42 answering member 4380 label Biography information for Jo Churchill
tabling member	4433 label Biography information for Thangam Debbonaire

1344143

registered interest
date	06/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with stakeholders on the efficacy of pancreatic enzyme replacement therapy as a treatment option for patients diagnosed with pancreatic cancer.
tabling member constituency	Weaver Vale
tabling member printed	Mike Amesbury
uin	28308
answer	answer is ministerial correction date of answer 13/07/2021 answer text <p>The National Health Service continues to work with Pancreatic Cancer UK to raise awareness of prescribed pancreatic enzyme replacement therapy (PERT), including sharing guidance with Cancer Alliances. The National Institute for Health and Care Excellence’s guidelines recommend that PERT should be considered for people with both operable and inoperable pancreatic cancer.</p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 13/07/2021 10:33:54 answering member 4380 label Biography information for Jo Churchill
tabling member	4667 label Biography information for Mike Amesbury

1332238

registered interest
date	11/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 10 June 2021 to Questions 11719, 11720, 11721 and 11722 on Pancreatic Cancer: Medical Treatments, if he will make an assessment of trends in the level of rates of prescription of pancreatic enzyme replacement therapy (PERT).
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	14188
answer	answer is ministerial correction date of answer 18/06/2021 answer text <p>The Department has no plans to do so.</p><p> </p><p>The following table shows the number of items that were prescribed for pancreatic enzyme replacement therapy medicines and dispensed in the community in England in each year from 2015 to 2019. No data is captured on the prescription form about the clinical indication for which a prescription is intended.</p><p><br></p><table><tbody><tr><td><p>Calendar Year</p></td><td><p>Total Items</p></td></tr><tr><td><p>2015</p></td><td><p>457,101</p></td></tr><tr><td><p>2016</p></td><td><p>488,341</p></td></tr><tr><td><p>2017</p></td><td><p>518,634</p></td></tr><tr><td><p>2018</p></td><td><p>563,787</p></td></tr><tr><td><p>2019</p></td><td><p>606,656</p></td></tr></tbody></table> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 14189 question first answered 18/06/2021 09:16:42 answering member 4380 label Biography information for Jo Churchill previous answer version 6938 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi